VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00564161

Enrollment

Registered

2007-11-27

Start date

2008-01-31

Completion date

2009-01-31

Last updated

2016-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Infants Developing Normally, Preterm Infants With White Matter Damage

Brief summary

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Weeks to 40 Weeks

Healthy volunteers

Inclusion criteria

* Preterm infants undergoing lumbar puncture.

Exclusion criteria

* Preterm with IVH or known infection or meningitis.

Outcome results